Researchers, physician-scientists and cardiac surgeons are leading technological and life-saving therapeutic advances to gain a deeper understanding of cardiovascular disease.

Objective Cardiovascular diseases (CVD) remain the leading cause of mortality globally, necessitating early risk ...

Lu Chen, M.D., is a cardiologist specializing in electrophysiology with MyMichigan Physicians Group.

BOSTON--(BUSINESS WIRE)--Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, ...

Vektor Medical to Showcase VITAL-EP Registry’s Atrial Fibrillation Results, Including Fast, Zero-Fluoro PVI+ Ablation Workflow, and New Atrial Flutter Capabilities Visit Vektor Medical at Booth 208 to ...

Visit Vektor Medical at Booth 208 to Learn More about vMap®, the VITAL-EP Registry’s AF Findings, and the Newly Released Atrial Flutter Workflow At this year’s meeting, a featured study titled "High ...

Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data ...

One initial treatment is a cardioversion, which involves using a defibrillator to deliver an electric shock to the heart to restore rhythm. It’s often successful, but sometimes only temporarily.

The 45-day post-implantation results support use of a next-generation device in people with atrial fibrillation, but caution is advised until longer-term results are available.

This article was co-authored with Emma Myer, a student at Washington and Lee University who studies Cognitive/Behavioral Science and Strategic Communication. In today’s digital age, social media has ...